Skip to content

Decoding Frontotemporal Dementia: Genes, Proteins and Prospects for Precision Medicine.

Aug 2026 · Current Alzheimer Research · Vol 23 · 0 citations
Medicine

TL;DR

An in-depth analysis of the epidemiology, clinical features, molecular pathologies, biomarkers, and potential therapeutic approaches concerning Frontotemporal Dementia, with a particular emphasis on the growing role of precision medicine.

Abstract

Frontotemporal Dementia is an umbrella term for several neurodegenerative disorders that have a similar presentation pattern, which is accompanied by neural damage and brain tissue loss in the frontal and temporal regions. Recent studies have observed that the heterogeneity of Frontotemporal Dementia (FTD) is reflected in clinical features, genetics, and molecular perspectives. Specifically, the major forms of pathology in FTD are linked to abnormal protein accumulation, which includes tau, TAR DNA-binding protein 43 (TDP-43), and fused in sarcoma (FUS). Moreover, genetic research on FTD has identified vital mutations in MAPT (Microtubule-associated protein Tau), GRN (Progranulin Gene), and C9ORF72 genes (Chromosome 9 open reading frame genes). Recent developments in neuroimaging, biomarker levels in body fluids, and molecular profiling have increased diagnostic precision, enabling earlier detection of disease subtypes. Neurofilament light chain (NfL), progranulin, and several other biomarkers, together with novel neuroimaging approaches, are currently being applied for disease classification, prognosis, and disease treatment monitoring. These developments have accelerated the application of precision medicine for FTD, including antisense oligonucleotides, progranulin-restorative drugs, tau-specific therapies, and gene therapy. Despite advances in elucidating the biology of FTD, no disease-modifying therapies have yet been developed, and treatments remain symptomatic until now. Undoubtedly, there are many challenges when taking into account variable presentation, overlapping pathologies, and the lack of robust biomarkers. The aim of this paper is to provide an in-depth analysis of the epidemiology, clinical features, molecular pathologies, biomarkers, and potential therapeutic approaches concerning FTD, with a particular emphasis on the growing role of precision medicine. Omics technologies, biomarker- based patient stratification, and hypothesis-driven clinical trials are undoubtedly essential steps towards personalized therapy for FTD.

View source

Similar papers

Open access Sep 2026

FRONTOTEMPORAL DEMENTIA - COMPREHENSIVE INSIGHTS INTO PATHOGENESIS, DIAGNOSIS, AND INNOVATIVE TREATMENTS

Frontotemporal dementia (FTD) is a clinically and genetically diverse group of neurodegenerative disorders predominantly affecting the frontal and anterior temporal lobes, leading to progressive changes in behavior, language, and executive function. FTD is the most common cause of young-onset dementia and third overall...

Piotr Wilczkowski, Aleksandra Palka, Natalia Krzysztofek et al. · 0 citations
Review Open access Aug 2026

Neurofilament impairment in neurodegenerative diseases: pathogenesis, biomarkers and diagnostic values

Neurofilament (NF) proteins, as integral components of the neuronal cytoskeleton, are essential for maintaining axonal structure and function. Genetic defects, aberrant post-translational modifications, and co-aggregation with other pathogenic proteins can disrupt NF homeostasis, leading to axonal injury and neuronal d...

Xiao-Wen Zhao, Yi-Ying Hu · 0 citations
Review Aug 2026

Emerging diagnostic biomarkers and therapeutic targets in Alzheimer's disease

A combination of biomarker-guided diagnostics with mechanism-based therapies might enable precision medicine approaches and improve clinical outcomes in AD.

Thumbar Kishan Dineshbhai, Dhvani Rafaliya, Aditya Singh et al. · 1 citation
Review Open access Aug 2026

Neurofilament Light Chain (NfL) in Neurodegenerative Diseases: Biological and Clinical Significance, Multi-Omics Integration, and AI-Driven Biomarker Modeling for Precision Therapy

The present review examines the biological and clinical relevance of NfL across major neurodegenerative diseases and critically discusses its combination with multi-omics, neuroimaging, and AI-based approaches and addresses ongoing methodological challenges.

Nawaf Alshammari, Reyaz Hassan, Mitesh Patel et al. · 0 citations
Review Open access Sep 2026

MicroRNAs as Diagnostic Biomarkers for Alzheimer’s Disease and Related Dementias

This review delineates the critical functions of specific miRNAs in orchestrating the three primary pathological pillars of AD: amyloid-β (Aβ) buildup, chronic neuroinflammation, and systemic oxidative stress.

Manivannan Subramanian, Aditi Singh, Amit Singh · 0 citations
Review Aug 2026

TDP-43-Associated Neurodegenerative Disease Conceptualization and Integrated Staging: A Review.

A pathobiological definition of disease is proposed to provide a road map for developing biomarkers that accurately reflect the underlying pathobiology of disease and for advancing therapeutic candidates that effectively target fundamental disease mechanisms.

M. Benatar, SJ Barmada, Gregory A. Jicha et al. · 1 citation

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.